MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584317 | Name: Elocalcitol
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Elocalcitol, also known as BXL 628, is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia.

Chemical Structure

Elocalcitol
Elocalcitol
CAS#199798-84-0

Theoretical Analysis

MedKoo Cat#: 584317

Name: Elocalcitol

CAS#: 199798-84-0

Chemical Formula: C29H43FO2

Exact Mass: 442.3247

Molecular Weight: 442.66

Elemental Analysis: C, 78.69; H, 9.79; F, 4.29; O, 7.23

Price and Availability

Size Price Availability Quantity
2mg USD 385.00 2 Weeks
5mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Elocalcitol; Ro 26-9228; Ro26-9228; Ro-26-9228; BXL 628; BXL628; BXL-628;
IUPAC/Chemical Name
Cyclohexanol, 3-((2E)-((3aS,7aS)-1-((1S,3E)-5-ethyl-5-hydroxy-1-methyl-3-heptenyl)-3,3a,5,6,7,7a-hexahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-5-fluoro-4-methylene-, (1R,3Z,5S)-
InChi Key
LRLWXBHFPGSUOX-GJQYOBCGSA-N
InChi Code
InChI=1S/C29H43FO2/c1-6-29(32,7-2)17-8-10-20(3)25-14-15-26-22(11-9-16-28(25,26)5)12-13-23-18-24(31)19-27(30)21(23)4/h8,12-14,17,20,24,26-27,31-32H,4,6-7,9-11,15-16,18-19H2,1-3,5H3/b17-8+,22-12+,23-13-/t20-,24+,26-,27-,28+/m0/s1
SMILES Code
O[C@@H]1C/C(C([C@@H](F)C1)=C)=C/C=C2[C@]3([H])CC=C([C@@H](C)C/C=C/C(O)(CC)CC)[C@@]3(C)CCC/2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
A vitamin D3 analog with diverse biological activities.
In vitro activity:
As illustrated in Fig. 1B, active RhoA protein expression in the HG group was significantly upregulated compared with the NC group (P<0.05), and treatment with 1,25-(OH)2D3 or BXL-628 significantly decreased the expression of active RhoA protein (both P<0.05). Additionally, ROCK activity was evaluated by measuring the phospho-MBS level (Fig. 1C). It was revealed that ROCK activity was significantly lower in the VD3 and BXL groups compared with the high glucose group (P<0.01). Reference: Exp Ther Med. 2017 May; 13(5): 1969–1976. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443178/
In vivo activity:
The VDR agonist elocalcitol inhibits lesion development in a validated mouse model of endometriosis, and exerts a protective effect on both the implantation and organization of transferred endometrial tissue. Reference: Hum Reprod. 2012 Jul;27(7):2010-9. https://pubmed.ncbi.nlm.nih.gov/22588001/
Solvent mg/mL mM
Solubility
Ethanol 20.0 45.18
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 442.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhang W, Yi B, Zhang K, Li A, Yang S, Huang J, Liu J, Zhang H. 1,25-(OH)2D3 and its analogue BXL-628 inhibit high glucose-induced activation of RhoA/ROCK pathway in HK-2 cells. Exp Ther Med. 2017 May;13(5):1969-1976. doi: 10.3892/etm.2017.4211. Epub 2017 Mar 9. PMID: 28565795; PMCID: PMC5443178. 2. Antinozzi C, Corinaldesi C, Giordano C, Pisano A, Cerbelli B, Migliaccio S, Di Luigi L, Stefanantoni K, Vannelli GB, Minisola S, Valesini G, Riccieri V, Lenzi A, Crescioli C. Potential role for the VDR agonist elocalcitol in metabolic control: Evidences in human skeletal muscle cells. J Steroid Biochem Mol Biol. 2017 Mar;167:169-181. doi: 10.1016/j.jsbmb.2016.12.010. Epub 2016 Dec 29. PMID: 28042053. 3. Mariani M, Viganò P, Gentilini D, Camisa B, Caporizzo E, Di Lucia P, Monno A, Candiani M, Somigliana E, Panina-Bordignon P. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012 Jul;27(7):2010-9. doi: 10.1093/humrep/des150. Epub 2012 May 15. PMID: 22588001. 4. Morelli A, Squecco R, Failli P, Filippi S, Vignozzi L, Chavalmane AK, Fibbi B, Mancina R, Luciani G, Gacci M, Colli E, Francini F, Adorini L, Maggi M. The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder. Am J Physiol Cell Physiol. 2008 May;294(5):C1206-14. doi: 10.1152/ajpcell.90634.2007. Epub 2008 Mar 19. PMID: 18353900.
In vitro protocol:
1. Zhang W, Yi B, Zhang K, Li A, Yang S, Huang J, Liu J, Zhang H. 1,25-(OH)2D3 and its analogue BXL-628 inhibit high glucose-induced activation of RhoA/ROCK pathway in HK-2 cells. Exp Ther Med. 2017 May;13(5):1969-1976. doi: 10.3892/etm.2017.4211. Epub 2017 Mar 9. PMID: 28565795; PMCID: PMC5443178. 2. Antinozzi C, Corinaldesi C, Giordano C, Pisano A, Cerbelli B, Migliaccio S, Di Luigi L, Stefanantoni K, Vannelli GB, Minisola S, Valesini G, Riccieri V, Lenzi A, Crescioli C. Potential role for the VDR agonist elocalcitol in metabolic control: Evidences in human skeletal muscle cells. J Steroid Biochem Mol Biol. 2017 Mar;167:169-181. doi: 10.1016/j.jsbmb.2016.12.010. Epub 2016 Dec 29. PMID: 28042053.
In vivo protocol:
1. Mariani M, Viganò P, Gentilini D, Camisa B, Caporizzo E, Di Lucia P, Monno A, Candiani M, Somigliana E, Panina-Bordignon P. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012 Jul;27(7):2010-9. doi: 10.1093/humrep/des150. Epub 2012 May 15. PMID: 22588001. 2. Morelli A, Squecco R, Failli P, Filippi S, Vignozzi L, Chavalmane AK, Fibbi B, Mancina R, Luciani G, Gacci M, Colli E, Francini F, Adorini L, Maggi M. The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder. Am J Physiol Cell Physiol. 2008 May;294(5):C1206-14. doi: 10.1152/ajpcell.90634.2007. Epub 2008 Mar 19. PMID: 18353900.
1: Yang WS, Yu H, Kim JJ, Lee MJ, Park SK. Vitamin D-induced ectodomain shedding of TNF receptor 1 as a nongenomic action: D3 vs D2 derivatives. J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):18-25. doi: 10.1016/j.jsbmb.2015.09.019. Epub 2015 Sep 15. PubMed PMID: 26385608. 2: Streng T, Andersson KE, Hedlund P, Gratzke C, Baroni E, D'Ambrosio D, Benigni F. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction. BJU Int. 2012 Jul;110(2 Pt 2):E125-31. doi: 10.1111/j.1464-410X.2011.10838.x. Epub 2012 Jan 30. PubMed PMID: 22288904. 3: Mariani M, Viganò P, Gentilini D, Camisa B, Caporizzo E, Di Lucia P, Monno A, Candiani M, Somigliana E, Panina-Bordignon P. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012 Jul;27(7):2010-9. doi: 10.1093/humrep/des150. Epub 2012 May 15. PubMed PMID: 22588001. 4: Sayegh L, Fuleihan Gel-H, Nassar AH. Vitamin D in endometriosis: a causative or confounding factor? Metabolism. 2014 Jan;63(1):32-41. doi: 10.1016/j.metabol.2013.09.012. Epub 2013 Oct 14. Review. PubMed PMID: 24135500. 5: Shapiro B, Redman TL, Zvara P. Effects of vitamin D analog on bladder function and sensory signaling in animal models of cystitis. Urology. 2013 Feb;81(2):466.e1-7. doi: 10.1016/j.urology.2012.10.027. PubMed PMID: 23374845. 6: Sagrinati C, Sottili M, Mazzinghi B, Borgogni E, Adorini L, Serio M, Romagnani P, Crescioli C. Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells. Transpl Int. 2010 Sep;23(9):914-23. doi: 10.1111/j.1432-2277.2010.01078.x. Epub 2010 Mar 18. PubMed PMID: 20302596. 7: Benigni F, Baroni E, Zecevic M, Zvara P, Streng T, Hedlund P, Colli E, D'Ambrosio D, Andersson KE. Oral treatment with a vitamin D3 analogue (BXL628) has anti-inflammatory effects in rodent model of interstitial cystitis. BJU Int. 2006 Mar;97(3):617-24. PubMed PMID: 16469037. 8: Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Sanvito F, Doglioni C, Adorini L. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol. 2006 Dec 15;177(12):8504-11. PubMed PMID: 17142748. 9: Fibbi B, Morelli A, Marini M, Zhang XH, Mancina R, Vignozzi L, Filippi S, Chavalmane A, Silvestrini E, Colli E, Adorini L, Vannelli GB, Maggi M. Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway. J Androl. 2008 Jan-Feb;29(1):70-84. Epub 2007 Aug 15. PubMed PMID: 17699803. 10: Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Fibbi B, Morelli A, Uskokovic M, Colli E, Maggi M. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):689-93. Epub 2007 Jan 22. PubMed PMID: 17241782. 11: Colli E, Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N, Scarpa R, Usai P, Olivieri L, Maggi M; BPH Italian study group. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2006 Jan;49(1):82-6. Epub 2005 Nov 15. PubMed PMID: 16310924. 12: Tiwari A. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. IDrugs. 2009 Jun;12(6):381-93. PubMed PMID: 19517319. 13: Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB, Gacci M, Colli E, Maggi M, Adorini L. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009 Apr 1;69(5):480-93. doi: 10.1002/pros.20896. PubMed PMID: 19107880. 14: Comeglio P, Chavalmane AK, Fibbi B, Filippi S, Marchetta M, Marini M, Morelli A, Penna G, Vignozzi L, Vannelli GB, Adorini L, Maggi M. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. J Endocrinol Invest. 2010 Nov;33(10):730-8. doi: 10.3275/6974. Epub 2010 Apr 12. PubMed PMID: 20386089. 15: Borgogni E, Sarchielli E, Sottili M, Santarlasci V, Cosmi L, Gelmini S, Lombardi A, Cantini G, Perigli G, Luconi M, Vannelli GB, Annunziato F, Adorini L, Serio M, Crescioli C. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. Endocrinology. 2008 Jul;149(7):3626-34. doi: 10.1210/en.2008-0078. Epub 2008 Mar 27. PubMed PMID: 18372324. 16: Tiwari A. Elocalcitol (BXL-628): a novel, investigational therapy for the therapeutic management of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2008 May;17(5):819-24. doi: 10.1517/13543784.17.5.819 . PubMed PMID: 18447607. 17: Füllhase C, Soler R, Gratzke C. New strategies in treating male lower urinary tract symptoms. Curr Opin Urol. 2014 Jan;24(1):29-35. doi: 10.1097/MOU.0000000000000003. Review. PubMed PMID: 24285261. 18: Bonaccorsi L, Marchiani S, Ferruzzi P, Muratori M, Crescioli C, Forti G, Maggi M, Baldi E. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells. Steroids. 2006 Apr;71(4):304-9. Epub 2005 Nov 9. Review. PubMed PMID: 16289173. 19: Maggi M, Crescioli C, Morelli A, Colli E, Adorini L. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J Endocrinol Invest. 2006 Jul-Aug;29(7):665-74. Review. PubMed PMID: 16957418. 20: Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010 Jun 1;33(3):475-88. doi: 10.1111/j.1365-2605.2009.00972.x. Epub 2009 Jun 8. Review. PubMed PMID: 19508330.